{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:07:12Z","timestamp":1793963232159,"version":"4.8.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020964","name":"Fusion Oriented REsearch for disruptive Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K22806"],"award-info":[{"award-number":["20K22806"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03075"],"award-info":[{"award-number":["21H03075"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005927","name":"Daiichi Sankyo Foundation of Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.phrs.2023.106693","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T06:30:18Z","timestamp":1676010618000},"page":"106693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma"],"prefix":"10.1016","volume":"189","author":[{"given":"Yukari","family":"Nagao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Asano-Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2023.106693_bib2","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int J. Cancer"},{"issue":"4 Suppl","key":"10.1016\/j.phrs.2023.106693_bib3","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2023.106693_bib5","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/1471-0528.14579","article-title":"Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome","volume":"124","author":"Cui","year":"2017","journal-title":"Bjog"},{"issue":"4","key":"10.1016\/j.phrs.2023.106693_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106693_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2559.2009.03231.x","article-title":"Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients","volume":"54","author":"Abeler","year":"2009","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.phrs.2023.106693_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.1999.5436","article-title":"Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases","volume":"74","author":"Mayerhofer","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PGP.0000000000000284","article-title":"Distant metastases in uterine leiomyosarcomas: the wide variety of body sites and time intervals to metastatic relapse","volume":"36","author":"Bartosch","year":"2017","journal-title":"Int J. Gynecol. Pathol."},{"key":"10.1016\/j.phrs.2023.106693_bib11","series-title":"Guidelines for treatment of uterine body neoplasm: Japan Society of Gynecologic Oncology (JSGO)","first-page":"2018","author":"Oncology","year":"2018"},{"key":"10.1016\/j.phrs.2023.106693_bib12","unstructured":"N.C.C. Network, NCCN Clinical Practice Guidelines in Oncology Version 1.2022 Uterine Neoplasms, 2022. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx\u3009."},{"issue":"4","key":"10.1016\/j.phrs.2023.106693_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E","article-title":"A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas","volume":"52","author":"Omura","year":"1983","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2023.106693_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106693_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"9829","key":"10.1016\/j.phrs.2023.106693_bib16","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2023.106693_bib17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10028","key":"10.1016\/j.phrs.2023.106693_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib19","doi-asserted-by":"crossref","first-page":"64.e1","DOI":"10.1016\/j.ajog.2019.07.030","article-title":"Copper ions are novel therapeutic agents for uterine leiomyosarcoma","volume":"222","author":"Kakuda","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2023.106693_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12967-016-0814-z","article-title":"PI3K\/AKT\/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma","volume":"14","author":"Babichev","year":"2016","journal-title":"J. Transl. Med"},{"issue":"10","key":"10.1016\/j.phrs.2023.106693_bib21","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-22-0100","article-title":"Aberrant activation of cell-cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma","volume":"28","author":"Yoshida","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.phrs.2023.106693_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2023.106693_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrd.2016.244","article-title":"Applications of chemogenomic library screening in drug discovery","volume":"16","author":"Jones","year":"2017","journal-title":"Nat. Rev. Drug Disco"},{"issue":"11","key":"10.1016\/j.phrs.2023.106693_bib24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/onc.2014.72","article-title":"Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer","volume":"34","author":"Bharadwaj","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2023.106693_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2019.03.002","article-title":"Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer","volume":"451","author":"Shimomura","year":"2019","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.phrs.2023.106693_bib26","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1158\/0008-5472.CAN-07-6862","article-title":"An in vitro multistep carcinogenesis model for human cervical cancer","volume":"68","author":"Narisawa-Saito","year":"2008","journal-title":"Cancer Res"},{"issue":"Pt 8","key":"10.1016\/j.phrs.2023.106693_bib27","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1242\/jcs.041889","article-title":"Redundant and differential regulation of multiple licensing factors ensures prevention of re-replication in normal human cells","volume":"122","author":"Sugimoto","year":"2009","journal-title":"J. Cell Sci."},{"issue":"6","key":"10.1016\/j.phrs.2023.106693_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41419-018-0733-4","article-title":"Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.phrs.2023.106693_bib29","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.18632\/oncotarget.6832","article-title":"Lanatoside C suppressed colorectal cancer cell growth by inducing mitochondrial dysfunction and increased radiation sensitivity by impairing DNA damage repair","volume":"7","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.phrs.2023.106693_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-003-0748-z","article-title":"Comparison of intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model","volume":"53","author":"Inoue","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib31","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/s41598-018-20617-5","article-title":"The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus","volume":"8","author":"Yeo","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2023.106693_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2020.00186","article-title":"Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of adriamycin","volume":"11","author":"Wang","year":"2020","journal-title":"Front Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2023.106693_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"issue":"5","key":"10.1016\/j.phrs.2023.106693_bib34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.phrs.2023.106693_bib35","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.31129","article-title":"Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways","volume":"142","author":"Cuppens","year":"2018","journal-title":"Int J. Cancer"},{"issue":"14","key":"10.1016\/j.phrs.2023.106693_bib36","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.phrs.2023.106693_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005850","article-title":"Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12","volume":"12","author":"M\u00e4kinen","year":"2016","journal-title":"PLoS Genet."},{"issue":"4","key":"10.1016\/j.phrs.2023.106693_bib38","doi-asserted-by":"crossref","first-page":"320.e1","DOI":"10.1016\/j.ajog.2019.05.018","article-title":"The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing","volume":"221","author":"Mas","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"15","key":"10.1016\/j.phrs.2023.106693_bib39","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.phrs.2023.106693_bib40","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1560","article-title":"The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas","volume":"13","author":"Hernando","year":"2007","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.phrs.2023.106693_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/CAD.0b013e3283442074","article-title":"Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway","volume":"22","author":"Italiano","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2011.03.001","article-title":"Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition","volume":"122","author":"Wong","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.phrs.2023.106693_bib43","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.25928","article-title":"A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C)","volume":"117","author":"Okuno","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2023.106693_bib44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/1078-0432.CCR-16-2149","article-title":"Potential targets' analysis reveals dual PI3K\/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas-an ENITEC group initiative","volume":"23","author":"Cuppens","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib45","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1038\/s41467-021-24677-6","article-title":"Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival","volume":"12","author":"Anderson","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2023.106693_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/biom11050659","article-title":"Cardiac glycosides as immune system modulators","volume":"11","author":"\u0160kubn\u00edk","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-2828(70)90029-5","article-title":"Effects of strophanthidin upon contraction and ionic exchange in rabbit ventricular myocardium: relation to control of active state","volume":"1","author":"Langer","year":"1970","journal-title":"J. Mol. Cell Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106693_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/hh0302.104562","article-title":"The Na+-Ca2+ exchanger is essential for the action of cardiac glycosides","volume":"90","author":"Reuter","year":"2002","journal-title":"Circ. Res"},{"issue":"7","key":"10.1016\/j.phrs.2023.106693_bib49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrm1150","article-title":"Regulation of cell death: the calcium-apoptosis link","volume":"4","author":"Orrenius","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"14","key":"10.1016\/j.phrs.2023.106693_bib50","first-page":"3807","article-title":"Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells","volume":"60","author":"McConkey","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2023.106693_bib51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bcp.2018.02.023","article-title":"Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt\/\u03b2-catenin\/c-Myc signaling pathway in human gastric cancer cell","volume":"150","author":"Hu","year":"2018","journal-title":"Biochem Pharm."},{"issue":"12","key":"10.1016\/j.phrs.2023.106693_bib52","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/biom9120792","article-title":"Lanatoside C induces G2\/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K\/AKT\/mTOR signaling pathways","volume":"9","author":"Reddy","year":"2019","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.phrs.2023.106693_bib53","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41419-018-1018-7","article-title":"Proscillaridin A exerts anti-tumor effects through GSK3\u03b2 activation and alteration of microtubule dynamics in glioblastoma","volume":"9","author":"Berges","year":"2018","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.phrs.2023.106693_bib54","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7150\/ijms.23270","article-title":"Proscillaridin A induces apoptosis, inhibits STAT3 activation and augments doxorubicin toxicity in prostate cancer cells","volume":"15","author":"He","year":"2018","journal-title":"Int J. Med Sci."},{"key":"10.1016\/j.phrs.2023.106693_bib55","doi-asserted-by":"crossref","first-page":"46134","DOI":"10.1038\/srep46134","article-title":"Lanatoside C, a cardiac glycoside, acts through protein kinase C\u03b4 to cause apoptosis of human hepatocellular carcinoma cells","volume":"7","author":"Chao","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phymed.2015.11.012","article-title":"Liver cancer cells are sensitive to Lanatoside C induced cell death independent of their PTEN status","volume":"23","author":"Durmaz","year":"2016","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.phrs.2023.106693_bib57","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/ijms23105637","article-title":"Genipin, an inhibitor of UCP2 as a promising new anticancer agent: a review of the literature","volume":"23","author":"Cho","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2023.106693_bib58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.mito.2009.12.143","article-title":"Uncoupling protein-2 and cancer","volume":"10","author":"Baffy","year":"2010","journal-title":"Mitochondrion"},{"key":"10.1016\/j.phrs.2023.106693_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.640720","article-title":"UCP2 as a potential biomarker for adjunctive metabolic therapies in tumor management","volume":"11","author":"Vallejo","year":"2021","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2023.106693_bib60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1073\/pnas.1317400111","article-title":"UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation","volume":"111","author":"Vozza","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.phrs.2023.106693_bib61","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s42255-020-00315-1","article-title":"KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth","volume":"2","author":"Raho","year":"2020","journal-title":"Nat. Metab."},{"issue":"5 Pt 1","key":"10.1016\/j.phrs.2023.106693_bib62","doi-asserted-by":"crossref","first-page":"C755","DOI":"10.1152\/ajpcell.1990.258.5.C755","article-title":"Mechanisms by which mitochondria transport calcium","volume":"258","author":"Gunter","year":"1990","journal-title":"Am. J. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ntt.2005.10.004","article-title":"The neurotoxic effects of prenatal cardiac glycoside exposure: a hypothesis","volume":"28","author":"Marx","year":"2006","journal-title":"Neurotoxicol Teratol."},{"key":"10.1016\/j.phrs.2023.106693_bib64","unstructured":"N.C.f.B. Information, PubChem Compound Summary for CID 442424, Genipin, 2022. \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Genipin\u3009."},{"issue":"1","key":"10.1016\/j.phrs.2023.106693_bib65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00776-005-0975-8","article-title":"Expression of a novel alternatively spliced UCP-2 transcript in osteogenic sarcoma","volume":"11","author":"Srivastava","year":"2006","journal-title":"J. Orthop. Sci."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182300049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182300049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:19:10Z","timestamp":1733847550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182300049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":65,"alternative-id":["S104366182300049X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106693","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106693"}}